Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli

被引：4
作者：
Tao, Lili [1 ]
Dahlquist, Ashley [2 ]
Harris, Harley [3 ]
Jacobs, Emily [3 ]
Wenzler, Eric [2 ]
Simner, Patricia J. [3 ]
Humphries, Romney [1 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Div Lab Med, Nashville, TN 37212 USA
[2] Univ Illinois, Coll Pharm, Chicago, IL USA
[3] Johns Hopkins Univ, Sch Med, Dept Pathol, Div Med Microbiol, Baltimore, MD 21205 USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2024年 / 68卷 / 10期
关键词：
antimicrobial combinations; beta-lactamases; antibiotic resistance; Stenotrophomonas; Enterobacteriaceae; gram-negative bacteria; IN-VITRO ACTIVITY; CEFTAZIDIME-AVIBACTAM; ESCHERICHIA-COLI; SUSCEPTIBILITY;
D O I：
10.1128/aac.00693-24
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Treatment options for carbapenem-resistant gram-negative bacilli (CR-GNB), especially metallo-beta-lactamase (MBL)-producing CR-GNB, are limited. Aztreonam (ATM) in combination with avibactam (AVI) has shown potential for treating MBL-producing carbapenem-resistant Enterobacterales (CREs) and Stenotrophomonas maltophilia. However, data on ATM in combination with other beta-lactamase inhibitors (BLIs) are limited. We performed a multicenter study to evaluate the in vitro activities of ATM in combination with AVI, vaborbactam (VAB), relebactam (REL), tazobactam (TAZ) as well as with their commercially available formulations against CREs and S. maltophilia using broth microdilution. AVI restored ATM activity for MBL-producing CREs (ATM: 9.8% vs ATM-AVI: 78.0%) and S. maltophilia (ATM: 0% vs ATM-AVI: 93.3%). REL also moderately restored activity of ATM in MBL-producing CREs (ATM: 9.8% vs ATM-REL: 42.7%) and S. maltophilia (ATM: 0% vs ATM-REL: 68.9%). VAB and TAZ demonstrated very limited effect on the activity of ATM against CR-GNB evaluated. The combination of ATM with ceftazidime-AVI (CAZ-AVI) demonstrated maximum activity against CREs. Although ATM-CAZ-AVI is the most potent regimen available for CREs and S. maltophilia, ATM-IMI-REL might be a reasonable alternative.
引用
收藏
页数：10
相关论文
共 42 条
[1]   Systematic literature review of the burden and outcomes of infections due to multidrug-resistant organisms in Europe: the ABOUT-MDRO project protocol [J].
Anaya-Baz, Blanca ;
Maldonado, Natalia ;
Palacios-Baena, Zaira R. ;
Palomo, Virginia ;
Pezzani, Maria Diletta ;
Chiesi, Sheila ;
Razzaboni, Elisa ;
Compri, Monica ;
Tacconelli, Evelina ;
Rodriguez-Bano, Jesus .
BMJ OPEN, 2020, 10 (05) :1-5
[2]   New antibiotics for bad bugs: where are we? [J].
Bassetti, Matteo ;
Merelli, Maria ;
Temperoni, Chiara ;
Astilean, Augusta .
ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS, 2013, 12
[3]   Meropenem/Vaborbactam Plus Aztreonam as a Possible Treatment Strategy for Bloodstream Infections Caused by Ceftazidime/Avibactam-Resistant Klebsiella pneumoniae: A Retrospective Case Series and Literature Review [J].
Belati, Alessandra ;
Bavaro, Davide Fiore ;
Diella, Lucia ;
De Gennaro, Nicolo ;
Di Gennaro, Francesco ;
Saracino, Annalisa .
ANTIBIOTICS-BASEL, 2022, 11 (03)
[4]   Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia [J].
Biagi, M. ;
Lamm, D. ;
Meyer, K. ;
Vialichka, A. ;
Jurkovic, M. ;
Patel, S. ;
Mendes, R. E. ;
Bulman, Z. P. ;
Wenzler, E. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (12)
[5]   Exploring Aztreonam in Combination with Ceftazidime-Avibactam or Meropenem-Vaborbactam as Potential Treatments for Metallo- and Serine-β-Lactamase-Producing Enterobacteriaceae [J].
Biagi, M. ;
Wu, T. ;
Lee, M. ;
Patel, S. ;
Butler, D. ;
Wenzler, E. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (12)
[6]   Aztreonam in combination with imipenem-relebactam against clinical and isogenic strains of serine and metallo-β-lactamase-producing enterobacterales [J].
Biagi, Mark ;
Lee, Michelle ;
Wu, Tiffany ;
Shajee, Aisha ;
Patel, Shitalben ;
Deshpande, Lalitagauri M. ;
Mendes, Rodrigo E. ;
Wenzler, Eric .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2022, 103 (02)
[7]   In Vitro Activity of Aztreonam-Avibactam against a Global Collection of Gram-Negative Pathogens from 2012 and 2013 [J].
Biedenbach, Douglas J. ;
Kazmierczak, Krystyna ;
Bouchillon, Samuel K. ;
Sahm, Daniel F. ;
Bradford, Patricia A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (07) :4239-4248
[8]   Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-β-Lactamase-Producing Enterobacterales Infections-In Vitro Susceptibility Testing [J].
Brauncajs, Malgorzata ;
Bielec, Filip ;
Malinowska, Marlena ;
Pastuszak-Lewandoska, Dorota .
PHARMACEUTICALS, 2024, 17 (03)
[9]   Interplay between β-lactamases and new β-lactamase inhibitors [J].
Bush, Karen ;
Bradford, Patricia A. .
NATURE REVIEWS MICROBIOLOGY, 2019, 17 (05) :295-306
[10]  
Cheung CHP., 2021, bioRxiv
12345